+

WO1998006733A1 - Sequence nucleotidique codant la proteine de type cd33 - Google Patents

Sequence nucleotidique codant la proteine de type cd33 Download PDF

Info

Publication number
WO1998006733A1
WO1998006733A1 PCT/US1996/013007 US9613007W WO9806733A1 WO 1998006733 A1 WO1998006733 A1 WO 1998006733A1 US 9613007 W US9613007 W US 9613007W WO 9806733 A1 WO9806733 A1 WO 9806733A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
polypeptide
amino acid
seq
cells
Prior art date
Application number
PCT/US1996/013007
Other languages
English (en)
Inventor
Jian Ni
Reiner L. Gentz
Craig A. Rosen
Original Assignee
Human Genome Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences, Inc. filed Critical Human Genome Sciences, Inc.
Priority to AU68445/96A priority Critical patent/AU6844596A/en
Priority to JP10509655A priority patent/JP2001502888A/ja
Priority to PCT/US1996/013007 priority patent/WO1998006733A1/fr
Priority to EP96928838A priority patent/EP0958304A4/fr
Publication of WO1998006733A1 publication Critical patent/WO1998006733A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a novel CD33-li e protein.
  • isolated nucleic acid molecules are provided encoding the CD33-like protein.
  • the present invention provides isolated nucleic acid molecules comprising a nucleic acid sequence encoding a CD33-like protein whose amino acid sequence is shown in Figure I [SEQ ID NO:2] or a fragment of the polypeptide.
  • the CD33-like protein gene contains an open reading frame encoding a protein of about 551 amino acid residues whose initiation codon is at position 37-39 of the nucleotide sequence shown in Figure 1 [SEQ ID NO. 1], with a leader sequence of about 15 amino acid residues, and a deduced molecular weight of about 60 kDa.
  • vectors comprising cis-acting control regions to the polynucleotide of interest.
  • Appropriate trans-acting factors either are supplied by the host, supplied by a complementing vector or supplied by the vector itself upon introduction into the host.
  • the invention provides a peptide or polypeptide comprising an epitope-bearing portion of a polypeptide of the invention.
  • the epitope of this polypeptide portion is an immunogenic or antigenic epitope of a polypeptide of the invention.
  • An "immunogenic epitope" is defined as a part of a protein that elicits an antibody response when the whole protein is the immunogen. These immunogenic epitopes are believed to be confined to a few loci on the molecule.
  • a region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope.”
  • the number of immunogenic epitopes of a protein generally is less than the number of antigenic epitopes. See, for instance, Geysen, H. M. et al, Proc. Natl Acad. Sci. USA
  • U.S. Patent No. 5,194,392 to Geysen (1990) describes a general method of detecting or determining the sequence of monomers (amino acids or other compounds) which is a topological equivalent of the epitope (i.e., a "mimotope") which is complementary to a particular paratope (antigen binding site) of an antibody of interest. More generally, U.S. Patent No. 4,433,092 to Geysen (1989) describes a method of detecting or determining a sequence of monomers which is a topographical equivalent of a ligand which is complementary to the ligand binding site of a particular receptor of interest. Similarly, U.S. Patent No. 5,480,971 to Houghten, R. A.
  • Further antagonist according to the present invention include soluble forms of CD33-like protein, i.e., CD33-like protein fragments that include the extracellular region from the full length receptor.
  • soluble forms of the receptor which may be naturally occurring or synthetic, antagonize CD33-like protein mediated signaling by competing with the cell surface CD33-like protein for binding to CD33 receptor ligands.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention se rapporte à une nouvelle protéine de type CD33. Elle se rapporte notamment à des molécules d'acide nucléique isolées qui codent ladite protéine de type CD33, à des vecteurs de recombinaison et à des cellules hôtes.
PCT/US1996/013007 1996-08-09 1996-08-09 Sequence nucleotidique codant la proteine de type cd33 WO1998006733A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU68445/96A AU6844596A (en) 1996-08-09 1996-08-09 Nucleotide sequence encoding the cd33-like protein
JP10509655A JP2001502888A (ja) 1996-08-09 1996-08-09 Ｃｄ３３様タンパク質をコードするヌクレオチド配列
PCT/US1996/013007 WO1998006733A1 (fr) 1996-08-09 1996-08-09 Sequence nucleotidique codant la proteine de type cd33
EP96928838A EP0958304A4 (fr) 1996-08-09 1996-08-09 Sequence nucleotidique codant la proteine de type cd33

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1996/013007 WO1998006733A1 (fr) 1996-08-09 1996-08-09 Sequence nucleotidique codant la proteine de type cd33

Publications (1)

Publication Number Publication Date
WO1998006733A1 true WO1998006733A1 (fr) 1998-02-19

Family

ID=22255589

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/013007 WO1998006733A1 (fr) 1996-08-09 1996-08-09 Sequence nucleotidique codant la proteine de type cd33

Country Status (4)

Country Link
EP (1) EP0958304A4 (fr)
JP (1) JP2001502888A (fr)
AU (1) AU6844596A (fr)
WO (1) WO1998006733A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0983078A1 (fr) * 1997-05-27 2000-03-08 Smithkline Beecham Corporation Adnc de la famille des sialoadhesines 4 (saf-4)
WO2001012646A1 (fr) * 1999-08-19 2001-02-22 Smithkline Beecham Corporation Anticorps d'agonistes et d'antagonistes de sialoadhesine facteur-1
US7998485B2 (en) 2006-05-11 2011-08-16 Universiteit Gent Sialoadhesin-related compositions and methods
US10479832B2 (en) 2014-03-31 2019-11-19 Universiteit Gent Method of treating bone disease

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007317333A1 (en) * 2006-11-02 2008-05-15 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 1 November 1994 (1994-11-01), SIMMONS ET AL.: "Isolation of a cDNA Encoding CD33, a Differentiation Antigen of the Myeloid Progenitor Cells", XP002965612, Database accession no. HUMCD33DA *
DATABASE GENBANK [online] 26 October 1995 (1995-10-26), HILLIER ET AL.: "Generation and analysis of 280,000 human expressed sequence tags", XP002965611, Database accession no. H71235 *
GENOME RES., vol. 6, no. 9, 1996, pages 807 - 828 *
J. IMMUNOL., vol. 141, no. 8, 1988, pages 2797 - 2800 *
See also references of EP0958304A4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0983078A1 (fr) * 1997-05-27 2000-03-08 Smithkline Beecham Corporation Adnc de la famille des sialoadhesines 4 (saf-4)
EP0983078A4 (fr) * 1997-05-27 2003-03-26 Smithkline Beecham Corp Adnc de la famille des sialoadhesines 4 (saf-4)
WO2001012646A1 (fr) * 1999-08-19 2001-02-22 Smithkline Beecham Corporation Anticorps d'agonistes et d'antagonistes de sialoadhesine facteur-1
US7998485B2 (en) 2006-05-11 2011-08-16 Universiteit Gent Sialoadhesin-related compositions and methods
US10479832B2 (en) 2014-03-31 2019-11-19 Universiteit Gent Method of treating bone disease

Also Published As

Publication number Publication date
AU6844596A (en) 1998-03-06
JP2001502888A (ja) 2001-03-06
EP0958304A1 (fr) 1999-11-24
EP0958304A4 (fr) 2002-01-16

Similar Documents

Publication Publication Date Title
US20090081727A1 (en) CD33-Like Protein
AU764278B2 (en) Human endokine alpha
US5942417A (en) CD44-like protein and nucleic acids
EP0929575A1 (fr) Nouveaux facteurs de croissance humains
US6521742B2 (en) Human endokine alpha
WO1998011138A1 (fr) Chimiokine alpha-4
EP0958304A1 (fr) Sequence nucleotidique codant la proteine de type cd33
EP0990000B1 (fr) Facteur de croissance 3 du tissu conjonctif
WO1998029438A2 (fr) Polypeptides de cortistatine
WO1998029438A9 (fr) Polypeptides de cortistatine
EP0814661A1 (fr) Enzymes 7, 8 et 9 de conjugaison d'ubiquitine
US20060142199A1 (en) CD-44 like protein
CA2284846A1 (fr) Facteur de croissance derive du muscle humain - proteine cardiaque et pancreatique (capp) et gene associe
EP0960198A1 (fr) Proteine de type cd44
US6576445B1 (en) Chemokine α-4
AU738116B2 (en) Chemokine beta-15
JP2004089192A (ja) Ｃｄ３３様タンパク質をコードするヌクレオチド配列
WO1998007862A9 (fr) Chemokine beta-16
WO1998007862A2 (fr) Chemokine beta-16
US20040132987A1 (en) Connective tissue growth factor-3
NZ505148A (en) Use of endokine alpha antagonists to diagnose and treat TNF-related disorders
EP0958374A1 (fr) Ligand i du type recepteur de t1
NZ514393A (en) Use of antibodies that bind to the endokine alpha polypeptide so as to decrease the level of endokine alpha activity in situ
CA2413012A1 (fr) Facteur de croissance endotheliale vasculaire 2 humain
MXPA98010779A (en) Quiniocina beta

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BG BR BY CA CN CZ EE FI GE HU IL JP KG KP KR KZ LT LV MD MN MX NO NZ PL RO RU SG SI SK TJ TM TR UA US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 509655

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 1998 509655

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996928838

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996928838

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1996928838

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载